Hester Biosciences
Ahmedabad: Hester Biosciences Ltd reported a 44% year-on-year increase in consolidated profit after tax (PAT) to Rs 20.6 crore for the Sept quarter of FY27. Revenue from operations rose 38% to Rs 97.9 crore, up from Rs 70.97 crore in the corresponding quarter last year. Consolidated EBITDA increased 55% to Rs 36.5 crore from Rs 23.6 crore. The EBITDA margin improved to 37% from 33% a year earlier. For the first half of FY27, revenue from operations grew 13% to Rs 175.2 crore. Consolidated PAT surged 271% to Rs 117.4 crore, up from Rs 31.6 crore in H1 FY26. The sharp increase in half-yearly profit was largely driven by an exceptional gain of Rs 85.8 crore. Under the revised terms, the outstanding principal was reduced from $12 million to $5 million. H1 consolidated EBITDA stood at Rs 148.3 crore, up from Rs 49.8 crore in the year-ago period.
The reported figure includes the impact of the exceptional gain. You Can Also Check: Gold Rate in Ahmedabad | Silver Rate in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad | Ahmedabad AQI | Weather in Ahmedabad | Petrol Price in Ahmedabad | Diesel Price in Ahmedabad | CNG Price in Ahmedabad | LPG Price in Ahmedabad Stay updated with the latest Ahmedabad news.
Hester said it would focus on expanding its poultry healthcare business, strengthening its animal healthcare portfolio and advancing vaccine development. Hester recognised the gain after restructuring a loan the Gates Foundation extended to its African subsidiary, Hester Africa. The lender also waived accrued interest and made the remaining loan interest-free. The company’s international operations remained broadly stable during the quarter. Supplies catered to institutional requirements, tenders and export orders across Asian and African markets. It also plans to improve manufacturing efficiency and pursue export opportunities through product registrations and market expansion. Download the TOI App.